BlackRock’s Trillium Therapeutics Inc. TRIL Stock Holding History

BlackRock’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,112,610	Closed	-$107M	–	5939
2021 Q3	$107M	Buy	6,112,610 +498,305	+9%	+$5.82M	﹤0.01%	2174
2021 Q2	$54.5M	Buy	+5,614,305	New	+$52.8M	﹤0.01%	2640

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

BlackRock's TRIL Position: Q4 2021 in Review

BlackRock sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 6,112,610 shares — an estimated $107M sold.

BlackRock first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $107M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

BlackRock reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
BlackRock sold 6,112,610 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $107M.
BlackRock first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
BlackRock's Trillium Therapeutics Inc. position peaked at $107M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on BlackRock's 13F filing for Q4 2021, filed 10 Feb 2022.